Securities Class Action Lawsuit Against Cytokinetics

Strategic Insights -

In a recent development, Kahn Swick & Foti (KSF), a prominent boutique securities litigation law firm, and its partner, former Louisiana Attorney General Charles C. Foti, Jr., have announced a securities class action lawsuit against Cytokinetics, Incorporated. The lawsuit alleges that the company and certain of its executives failed to disclose material information during a specific period, violating federal securities laws. This led to a decline in the price of Cytokinetics' shares after two critical disclosures were made. The deadline for investors to file lead plaintiff applications is November 17, 2025.

Key Takeaways:

  • The lawsuit is pending in the United States District Court for the Northern District of California, case number 25-cv-07923.
  • The Class Period is from December 27, 2023 to May 6, 2025, inclusive, during which time investors purchased or acquired Cytokinetics' securities.
  • Cytokinetics is charged with failing to disclose material information, specifically the FDA's decision not to convene an advisory committee meeting and the company's decision to submit a New Drug Application without a Risk Evaluation and Mitigation Strategy.
  • The lawsuit was filed by KSF and is being led by Managing Partner Lewis Kahn, who can be contacted for more information.
  • Investors who purchased Cytokinetics' securities and wish to discuss their legal rights may do so without obligation or cost to them by contacting KSF.
  • To serve as a lead plaintiff, investors must petition the Court by November 17, 2025.

Statistics:

  • The price of Cytokinetics' shares fell after the critical disclosures, closing at $33.04 per share on May 7, 2025.
  • KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.